1. A pharmaceutical composition comprising suitable pharmaceutical excipients as well as an in vivo amount of a pegylated pegylated prodrug of recombinant human growth hormone (rhGH) conjugate in vivo, wherein the PEG is coupled to rhGH via a self-hydrolyzable (self-cleavable) time linker； wherein said prodrug conjugate is characterized in that:! (1): the conjugate has a GH activity of less than 5% with respect to native growth hormone without PEG； and! (2): the linker self-hydrolysis rate is such that the in vivo half-life is from 10 hours to 600 hours! 2. The pharmaceutical composition according to claim 1, wherein the self-hydrolysis rate is such that the in vivo half-life is up to 5 times shorter than the in-vitro half-life of the corresponding PEGylated hGH prodrug conjugate. ! 3. The pharmaceutical composition according to claim 2, wherein the in vivo half-life is up to 3 times shorter than the in vitro half-life of the corresponding PEGylated hGH prodrug conjugate. ! 4. The pharmaceutical composition according to claim 2 or 3, wherein the in vivo half-life is up to 2 times shorter or almost identical to the in vitro half-life of the corresponding PEGylated hGH prodrug conjugate. ! 5. The pharmaceutical composition according to claim 1 and 2, where the composition is a composition for subcutaneous administration, intramuscular injection or intravenous administration. ! 6. The pharmaceutical composition according to claim 1 and 2, where the pegylated prodrug has a total load of PEG on the molecule of growth hormone, which is at least 25 kDa. ! 7. The pharmaceutical composition according to claim 1 and 2, where the prodrug conjugate has a chemical structure (A):! ! g1. Фармацевтическая композиция, содержащая подходящие фармацевтические наполнители, а также содержащая in vivo клинически эффективное для человека количество конъюгата ПЭГилированного пролекарства рекомбинантного человеческого гормона роста (рчГР), где ПЭГ связан с рчГР через самогидролизуемый (самор
